Clinical Trials

Do you or your child have dyslipidemia? This study is exploring how different diagnostic tests can help us understand how lipid disorders, including high blood cholesterol and high blood triglycerides, affect the body. Information from this study may help improve the way lipid disorders are diagnosed or treated in the future. Participants in this study must be at least 2 years old. The study is being conducted in Bethesda, Maryland.

Are you a black man or women who has obesity and lives in Washington D.C.? This study aims to understand the health and health needs of people in predominately black churches in Washington, D.C. This information will help researchers design programs to improve heart health in these communities. To participate in this study, you must be between 19 and 85 years old and attend one of the churches in the study. This study is based in Bethesda, Maryland.

Are you an adult who has overweight or obesity and would be interested in a weight-loss study? This study is testing whether a medicine called phentermine is safe and effective for treating obesity over a long period. This study has multiple locations in the United States.

Are you an adult with sleep apnea, overweight, or obesity, or do you just want to help research? This study is looking at how sleep apnea changes fat tissue in the body. The researchers will examine whether these changes in fat tissue may raise the risk of heart and blood vessel diseases. To participate in this study, you must be between 18 and 60 years old with obstructive sleep apnea and healthy without any chronic diseases. This study takes place in Rochester, Minnesota.

his trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice.

The main goal of this study is to determine whether the treatment will lead to a complete absence of severe vaso-occlusive events (VOEs) in patients with severe SCD.

Are you or your child at least 13 years old and have sickle cell disease? In this stidy, researchers are trying to find out if a new medication improves the success of a blood stem cell transplant. People 13 years old or older who are eligible for a blood stem cell transplant to treat sickle cell disease may be able to participate. Healthy family members over age 13 who are matched to transplant recipients are also needed to donate blood for the study. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

Are you at least 18 years old and have sickle cell disease and taking the medication Hydroxyurea? For this study, researchers testing are tool for measuring oxygen levels, blood flow, and the makeup of skin and muscle in patients with sickle cell disease. To participate in this study, you must be at least 18 years old and have sickle cell disease and also be taking the medication Hydroxyurea. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

Are you at least 18 years old and have sickle cell disease? People with sickle cell disease often have problems with their heart, brain, kidneys, liver, and lungs as they age. These problems may improve after transplant. Researchers in this study are trying to learn how and why this happens. To participate in this study, you must be at least 18 years old and have sickle cell disease. You must also have a history of problems with your heart, lungs, or other criteria that the study doctor will discuss with you. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.